News & Updates
Faces of Lung Cancer Report
Reflection of COVID-19. The annual report is now available!
The Lung Cancer Canada Summer Studentship Grant Program provides support for highly qualified applicants in all areas of lung cancer health research at all post-secondary stages to add to their experience by engaging in health research in Canada. A number of $5,000 (CDN) grants are available as a one-time funding opportunity.
Please contact Lung Cancer Canada ([email protected]) if you are a patient or caregiver of a patient on Keytruda. Your experience with this treatment is a crucial part of the decision process!
Tenacious Dr. Terry-Nan Tannenbaum, renowned public health physician, fought super-bugs, SARS, tuberculosis and HIV in others for decades until her fight became personal when she was diagnosed with terminal lung cancer.
Dr. Rosalyn Juergens' interview with Pauline Chan at CTV News on the promising results from the drug Opdivo (Nivolomab).
pCODR releases initial recommendation of Opdivo (nivolumab) for metastatic NSCLC (both squamous and non-squamous); on or after chemotherapy. No test required.
This is a great news for NSCLC patients! We hope to see more like this for other types of lung cancer.
Your experience with cancer care in Ontario depends greatly on the type of cancer you have, the kind of treatment you are prescribed, your age and family income – all of which can make or break the timeliness and quality of care you receive. Ontario’s two-tiered cancer drug system includes widely different drug reimbursement models and variable safety standards and support for patients who take their cancer medications at home versus in a hospital or cancer clinic.
Some good news for Canada's deadliest cancer:
The Canadian Task Force on Preventive Health Care now recommends screening using low-dose CT scans in high-risk adults aged 55-74 years who are current or former smokers with a smoking history of at least 30 pack-years, defined as the average number of packs smoked daily multiplied by the number of years of smoking. This is big step in the fight against lung cancer! [Canadian Cancer Statistics, 2015]
In February 2016, 350 cancer specialists from across Canada gathered in Vancouver for the 16th annual Canadian Lung Cancer Conference chaired by Dr. Barb Melosky and Dr. Cheryl Ho. Participants included medical oncologists, radiation oncologists, surgeons, pathologists, oncology nurses as well as members of the pharmaceutical industry, who came together with a common interest in improving the care of patients with lung cancer in Canada.
Good news for lung cancer patients, OPDIVO™ (nivolumab), first-ever immunotherapy for advanced or metastatic NSCLC, gets Health Canada approval.
LCC is looking for lung cancer patients and their caregivers, in Canada or the US, who have received either Cyramza (Ramucirumab), Keytruda (Pembrolizumab) or Tagrisso (Osimertinib) who are willing to share their experience (anonymously) with the drug.